

Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

February 12, 2021

BSE Limited

P. J. Towers, Dalal Street, Mumbai - 400 001 Scrip Code-540025 National Stock Exchange of India Ltd.,

Exchange Plaza, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051

Trading Symbol-ADVENZYMES

Subject: Outcome of Board Meeting held on February 12, 2021

Ref: ISIN: INE837H01020

With reference to the Board Meeting notice dated February 02, 2021, we hereby inform that the Board of Directors in its meeting held on February 12, 2021 (commenced at 10:45 a.m. and concluded at 11:35 a.m.) has *inter-alia*, transacted the following business:

- ➤ Approved the Unaudited Financial Results of the Company (Standalone & Consolidated) for the quarter and nine months ended December 31, 2020.
- ➤ Approved the allotment of 4,500 Equity Shares of face value of Rs. 2/- at an exercise price of Rs. 60/- per share pursuant to exercise of options under the Employees Stock Option Scheme, 2015.

In view of the aforesaid, we hereby enclose the following:

- ➤ Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2020 along with the Limited Review Report issued by B S R & Co. LLP, Statutory Auditors of the Company.
- ➤ Press Release and Earnings Presentation for the quarter and nine months ended December 31, 2020.

The aforesaid financial results along with Limited Review Report and other documents as mentioned above, are also being uploaded on the website of the Company, i.e. www.advancedenzymes.com

This is for your information and for public at large.

Thanking you,
Yours faithfully,
For Advanced Enzyme Technologies Limited

Sd/-Sanjay Basantani Company Secretary & Head -Legal

Encl: As above

BSR&Co.LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Telephone: +91 22 6257 1000 Fax: +91 22 6257 1010

Limited review report

To Board of Directors of Advanced Enzyme Technologies Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Advanced Enzyme Technologies Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Sr. No.	Name of entity Relationship			
1	Advanced Bio-Agro Tech Limited	Subsidiary		
2	Advanced Enzytech Solutions Limited	Wholly owned subsidiary		
3	Advanced Enzymes USA, Inc. ("AEU")	Wholly owned subsidiary		
4	Cal India Foods International ("CAL")	Wholly owned subsidiary of AEU		
5	Advanced Supplementary Technologies Corporation	Wholly owned subsidiary of AEU		
7	Dynamic Enzymes, Inc.	Wholly owned subsidiary of AEU		
6	Enzyme Innovation, Inc.	Wholly owned subsidiary of CAL		
8	JC Biotech Private Limited	Subsidiary		
9	Advanced Enzymes (Malaysia) Sdn. Bhd	Wholly owned subsidiary		
10	Advanced Enzymes Europe B.V. ("AEBV")	Wholly owned subsidiary		
11	Evoxx Technologies GmbH	Wholly owned subsidiary of AEBV		

Advanced Enzyme Technologies Limited

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial statements / financial information / financial results of three subsidiaries included in the Statement, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 285 million and Rs. 770 million, total net profit after tax of Rs 38 million and Rs. 85 million and total comprehensive income of Rs. 39 million and Rs. 87 million, for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020, respectively, before giving effect of consolidation adjustments, as considered in the consolidated unaudited financial results. These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

7. The Statement includes the interim financial statements/ financial information/ financial results of three subsidiaries which have not been reviewed/audited, whose interim financial statements/ financial information/ financial results reflect total revenue of Rs. 63 million_and Rs. 135 million, total net profit after tax of Rs. 28 million and Rs. 55 million and total comprehensive income of Rs. 28 million and Rs. 55 million for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020, respectively, before giving effect of consolidation adjustments, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Co. LLP** *Chartered Accountants*Firm's Registration No. 101248W/W-100022

SADASHIV SHANKAR SHETTY

Digitally signed by SADASHIV SHANKAR SHETTY Date: 2021.02.12 11:50:32 +05'30'

Sadashiv Shetty

Partner
Membership No: 048648
ICAI UDIN: 21048648AAAAAK3815

Mumbai 12 February 2021

Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.
Tel No.91-22-41703220 Fax No.: +91-22-25835159

Website: www.advancedenzymes.com, Email Id:sanjay@advancedenzymes.com

Statement of unaudited consolidated financial results for the quarter and nine months ended 31 December 2020

(₹ in million except per share data)

		Quarter ended			Nine months ended Year ended			
	Particulars	31-Dec-20 30-Sep-20 31-Dec-19			31-Dec-20 31-Dec-19		31-Mar-20	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
		Unadated	o i i u u u i u	Unadated	0114441104	0114441104	7.000.000	
1	Revenue from operations	1,377,38	1,203,86	1,119,44	3,686,25	3,337,22	4,439,86	
	Other Income (refer note iv and vi)	13,48	5.82	12.05	71,64	38.00	56.43	
	Total Income (1+2)	1,390.86	1,209.68	1,131.49	3,757.89	3,375.22	4,496.29	
4	Expenses			,	,	,	,	
	(a) Cost of materials consumed	285.64	177.51	233.02	704.13	707.06	906.00	
	(b) Purchases of stock-in-trade	0.28	0.00	0.46	0.28	1.74	2.30	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	4.14	8.16	(33.96)	(17.67)	(79.67)	(99.21)	
	(d) Employee benefits expense	213.73	214.16	191.35	638.86	600.59	801.92	
	(e) Finance costs (including exchange difference)	3.25	3.85	7.92	11.67	23.42	30.36	
	(f) Depreciation and amortisation expense	65.01	68.00	63.94	200.23	191.25	257.78	
	(g) Other expenses	209.74	218.90	199.87	594.39	571,23	805.57	
	Total Expenses	781.79	690.58	662.60	2,131.89	2,015.62	2,704.72	
5	Profit before exceptional item and tax (3-4)	609.07	519.10	468.89	1,626.00	1,359.60	1,791.57	
6	Exceptional item	-	-	-	-	-	-	
7	Profit before tax (5-6)	609.07	519.10	468.89	1,626.00	1,359.60	1,791.57	
8	Tax expense							
	Current tax	142.00	159.31	121.61	443.31	375.37	502.77	
	Deferred tax charge / (credit)	24.04	(25.80)	1.70	6.02	(19.48)	(41.69)	
_	Total tax expense	166,04	133,51	123,31	449,33	355.89	461.08	
	Net profit for the period (7-8)	443,03	385,59	345.58	1,176.67	1,003.71	1,330,49	
10	Other comprehensive income							
	A (i) Items that will not be reclassified to profit or loss	(0.74)		0.57	(4.74)	(0.47)	(5.70)	
	Remeasurements of defined benefit liability/(asset)	(0.74)	0.28	0.57	(1.71)	(3.47)	(5.70)	
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.21	(0.06)	(0.20)	0.51	0.99	1.65	
	B (i) Items that will be reclassified to profit or loss	(00.00)	(00.00)	EO 45	(400.50)	404.00	200.07	
	Exchange differences in translating financial statements of foreign operations (ii) Income tax related to items that will be reclassified to profit or loss	(29.06)	(98.06)	52.45	(108.58)	134.93	398.87	
	Total Other comprehensive income	(29,59)	(97.84)	52.82	(109.78)	132,45	394.82	
	Total Other comprehensive meanic	(23,53)	(57.64)	52,62	(103,76)	132,43	334,62	
11	Total comprehensive income (9+10)	413.44	287.75	398.40	1,066.89	1,136.16	1,725.31	
					·		·	
12	Net profit attributable to:							
	Shareholders of the Company	430.88	371.86	336.05	1,145.22	979.62	1,292.94	
	Non-controlling interest	12.15	13.73	9.53	31.45	24.09	37.55	
13	Other comprehensive income attributable to:							
	Shareholders of the Company	(29,63)	(98,18)	53.09	(110,08)	132,76	395.09	
	Non-controlling interest	0.04	0.34	(0.27)	0.30	(0.31)	(0.27)	
14	Total comprehensive income attributable to:] 3.04	0.04	(5.27)	5.50	(3.01)	(0.27)	
	Shareholders of the Company	404.04	070 00	200 11	4.005.44	4 440 00	4 000 00	
	· · ·	401.24	273.68	389.14	1,035.14	1,112.38	1,688.03	
	Non-controlling interest	12.20	14.07	9.26	31.75	23.78	37.28	
	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223,45	223,36	223.35	223.45	223,35	223,36	
15							8,173.17	
15 16	Other equity							
	Other equity Earnings Per Share of ₹ 2 each (not annualized)							
16		3.86	3.33	3.01	10.25	8.77	11.58	

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Read. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email ld :sanjay@advancedenzymes.com

Notes:

- (i) The above unaudited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.), Advanced Enzymes (Malaysia) Sdn. Bhd. (Malaysia), Advanced Enzymes Europe B.V. (Netherlands) and Evoxx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".
- (ii) The above unaudited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 12 February 2021. The above results have been subjected to 'limited review' by the statutory auditors of the Company and they have issued an unmodified report. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- (iii) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.
- (iv) Other income for nine months ended 31 December 2020 includes Rs. 40.7 million of grant received from the Government of United States of America ("USA") by subsidiaries Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.) and Enzyme Innovation, Inc. (U.S.A.) under CARES Act ("Act") as Paycheck Protection Program.
- (v) The Company has allotted 45,450 equity shares during the quarter and nine months ended 31 December 2020 to employees under the 'AETL Employee Stock Option Scheme 2015'. ("AETL ESOS 2015").
- (vi) During the quarter the Group has concluded transfer and assignment of its leasehold rights in the property situated at Jalna (BT park), Maharashtra with a tripartite agreement with Maharashtra Industrial Development Corporation ('MIDC') and the transferees to relinquish its rights on the said leasehold property. Accordingly, the gain on the transaction aggregating Rs 7.2 million is included under "Other Income".
- (vii) During the quarter the Company has computed its corporate tax liability as per lower tax rate available under Section 115BAA of the Income Tax Act, 1961 as introduced by the taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has remeasured its deferred tax assets/ liability including unutilized Minimum Alternate Tax credit asset aggregating Rs 27.08 million and is expensing it out equally over a period of two quarters beginning from the current quarter.
- (viii) On 11 January 2021, the Group completed the acquisition of 51% of the paid up equity share capital in SciTech Specialties Private Limited ('SSPL') for a total consideration of Rs 316.26 million. SSPL is technology based contract manufacturing company specialising in effervescent granules and tablets.
- (ix) The Group has considered internal and external information while assessing recoverability of its assets disclosed in the financial statement upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Group expects to recover the carrying amount of these assets. The Group has also considered the impact of COVID-19 on the business for the foreseeable future and has concluded that the Group has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Group will continue to closely monitor any material changes to future economic conditions.

SADASHIV SHANKAR SHETTY

Digitally signed by SADASHIV SHANKAR SHETTY Date: 2021.02.12 11:50:00 +05'30'

Place: Thane

Dated: 12 February 2021

By Order of the Board of Directors

For Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018

MUKUND MADHUSUDAN KABRA Olgifally signed by MUKUND MADHUSUDAN KABRA

NU CHIN, 3-Hannachtra,

NU CHIN,

M.M. Kabra Wholetime Director DIN: 00148294